Related Experiment Videos
[MORPHOFUNCTIONAL PARAMETERS OF BLOOD CELLS OF THE RAT WITH 1,2-DIMETHYLHYDRAZINE-INDUCED COLON CARCINOGENESIS].
Tsitologiia I Genetika
|July 29, 2015
Summary
Dimethylhydrazine (DMH)-induced colon cancer in rats causes red blood cell hemolysis and anemia. This model is valuable for studying cancer and developing treatments for blood system changes.
Area of Science:
- Hematology
- Oncology
- Toxicology
Context:
- Colon carcinogenesis is a complex process often accompanied by hematological alterations.
- Dimethylhydrazine (DMH) is a chemical agent used to induce colon tumors in rodent models.
- Understanding blood cell morphofunctional changes is crucial for evaluating cancer progression and treatment efficacy.
Purpose:
- To investigate the morphofunctional parameters of blood cells in rats during DMH-induced colon carcinogenesis.
- To analyze the hematological changes associated with tumor development and post-treatment periods.
- To assess the suitability of the DMH-induced colon cancer model for further research.
Summary:
- DMH administration led to red blood cell hemolysis, indicated by decreased Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular Hemoglobin Concentration (MCHC), and increased reticulocytes and indirect bilirubin after 20 weeks.
- Monocytes, platelets, and eosinophilic granulocytes showed moderate increases during tumor development.
- After discontinuing DMH for 6 weeks (26 weeks total), rats exhibited reduced hemoglobin and erythrocytes, with persistent increases in monocytes and platelets, mirroring anemia with thrombocytosis seen in human cancers.
Impact:
- The DMH-induced colon cancer model effectively replicates cancer-associated hematological changes, including anemia and thrombocytosis.
- This model is suitable for studying carcinogenesis mechanisms and screening novel antineoplastic drugs.
- It also provides a platform for developing therapeutic strategies to correct cancer-related hematopoietic system dysfunctions.